As shown in Table 3, one completed phase II trial has evaluated the antitumor activity of DNA hypomethylating agent azacitidine (CC-486) in combination with anti-PD-1 antibody (durvalumab) in metastatic ER-positive/HER2-negative BC and other types of cancer (NCT02811497). The gene discussed is ERBB2; the disease is breast cancer.